Deltex Medical Group PLC Two additional US platform programme accounts
January 18 2017 - 1:00AM
RNS Non-Regulatory
TIDMDEMG
Deltex Medical Group PLC
18 January 2017
18 January 2017
Deltex Medical Group plc
("Deltex Medical", "Deltex" or "the Company")
Two additional US platform programme accounts: 30 platform
accounts milestone passed
Deltex Medical Group plc (AIM: DEMG), the global leader in
oesophageal Doppler monitoring ("ODM"), is pleased to announce that
it has added two new accounts to its platform programme in the
USA.
Both new hospitals are in the North-East, one with 300 and the
second with 400 beds. The hospitals expect to use 40 and 50 probes
a month once they have completed their initial implementation
programmes which are scheduled to start in January and February
respectively.
The two new hospitals are the 29(th) and 30(th) US platform
programme accounts and the 7(th) and 8(th) in the North-East
territory. Deltex is recruiting an additional clinical trainer to
support hospitals implementing ODM in this territory.
Ewan Phillips, Deltex Medical's Chief Executive, commented:
"Opening our 30(th) platform account in the USA is a key
development in our US expansion plan as it gives us our planned
critical mass of substantial hospital customers from which to
expand going forward as well as generating returns from developing
recurring, high margin revenues from supporting implementation of
our products in these accounts."
For further information, please contact:-
Deltex Medical Group 01243 774 837
plc investorinfo@deltexmedical.com
Nigel Keen, Chairman
Ewan Phillips, Chief
Executive
Jonathan Shaw, Group
Finance Director
Nominated Adviser &
Broker
Arden Partners plc 020 7614 5900
Chris Hardie
Financial Public Relations
IFC Advisory 0203 053 8671
Tim Metcalfe
Graham Herring
Heather Armstrong
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's ODM is the only technology to
measure continuously blood flow in the central circulation in real
time. Minimally invasive, easy to set up and quick to focus, the
technology generates a low-frequency ultrasound signal, which is
highly sensitive to changes in flow and measures them immediately.
Deltex has been the only company in the enhanced haemodynamic space
to build a robust and credible evidence base proving the clinical
and economic benefits of its core technology, ODM. Randomised,
controlled trials using Doppler have demonstrated that early fluid
management intervention will reduce post-operative complications,
reduce intensive care admissions, and reduce the length of hospital
stay.
Company goal
ODM is increasingly recognised as a standard of care for
patients undergoing major surgery and in critical care. The broader
clinical area of haemodynamic management of which ODM is a core
constituent is also now becoming widely accepted as an important
major new medical modality. Consequently, the Company's focus is on
maximising value from the opportunities presented as enhanced
haemodynamic management is adopted into routine clinical practice
around the world.
The Company is currently in the implementation phase of
achieving this goal in a number of territories worldwide, operating
directly in the UK, USA, Spain and Canada and through distribution
arrangements in a further 30 countries.
There are over 3,200 monitors installed in hospitals around the
world and around 700,000 patients have been treated to date using
Deltex Medical's single patient disposable probes.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASFLESWFWSEDF
(END) Dow Jones Newswires
January 18, 2017 02:00 ET (07:00 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2024 to May 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From May 2023 to May 2024